USD 0.0
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2022 | 494.5 Million USD | -19.81% |
2021 | 616.68 Million USD | 56.09% |
2020 | 395.09 Million USD | -24.73% |
2019 | 524.87 Million USD | 12.34% |
2018 | 467.22 Million USD | 71.04% |
2017 | 273.16 Million USD | -13.3% |
2016 | 315.08 Million USD | 55.53% |
2015 | 202.58 Million USD | 517.1% |
2014 | 32.82 Million USD | 27.37% |
2013 | 25.77 Million USD | 4311.86% |
2012 | 584.17 Thousand USD | 62.57% |
2011 | 359.33 Thousand USD | -40.5% |
2010 | 603.95 Thousand USD | 71.06% |
2009 | 353.07 Thousand USD | 15040.22% |
2008 | 2332.00 USD | -29.01% |
2007 | 3285.00 USD | -99.3% |
2006 | 471.78 Thousand USD | 1351.65% |
2005 | 32.5 Thousand USD | -90.46% |
2004 | 340.53 Thousand USD | 0.22% |
2003 | 339.76 Thousand USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 Q1 | 587.48 Million USD | 18.8% |
2023 Q2 | 654.64 Million USD | 11.43% |
2022 Q4 | 494.5 Million USD | 1.87% |
2022 Q1 | 629.43 Million USD | -9.4% |
2022 FY | 494.5 Million USD | -19.81% |
2022 Q3 | 485.4 Million USD | -2.21% |
2022 Q2 | 496.36 Million USD | -21.14% |
2021 Q4 | 694.76 Million USD | 11.8% |
2021 Q1 | 382.72 Million USD | -3.13% |
2021 Q2 | 593.38 Million USD | 55.04% |
2021 Q3 | 621.46 Million USD | 4.73% |
2021 FY | 616.68 Million USD | 56.09% |
2020 Q4 | 395.09 Million USD | -13.51% |
2020 Q3 | 456.8 Million USD | 0.87% |
2020 Q2 | 452.85 Million USD | -6.69% |
2020 Q1 | 485.32 Million USD | -7.53% |
2020 FY | 395.09 Million USD | -24.73% |
2019 FY | 524.87 Million USD | 12.34% |
2019 Q2 | 532.42 Million USD | 8.36% |
2019 Q4 | 524.87 Million USD | -5.29% |
2019 Q1 | 491.36 Million USD | 17.95% |
2019 Q3 | 554.2 Million USD | 4.09% |
2018 Q2 | 193.05 Million USD | -1.51% |
2018 Q4 | 416.58 Million USD | 14.32% |
2018 FY | 467.22 Million USD | 71.04% |
2018 Q1 | 196 Million USD | -12.89% |
2018 Q3 | 364.4 Million USD | 88.76% |
2017 FY | 273.16 Million USD | -13.3% |
2017 Q1 | 283.12 Million USD | -10.14% |
2017 Q2 | 288.57 Million USD | 1.92% |
2017 Q3 | 346.47 Million USD | 20.07% |
2017 Q4 | 225 Million USD | -35.06% |
2016 FY | 315.08 Million USD | 55.53% |
2016 Q1 | 184.81 Million USD | -8.77% |
2016 Q2 | 216.17 Million USD | 16.97% |
2016 Q3 | 206.56 Million USD | -4.45% |
2016 Q4 | 315.08 Million USD | 52.54% |
2015 FY | 202.58 Million USD | 517.1% |
2015 Q2 | 41.56 Million USD | 32.97% |
2015 Q1 | 31.25 Million USD | -4.79% |
2015 Q3 | 178.51 Million USD | 329.5% |
2015 Q4 | 202.58 Million USD | 13.48% |
2014 Q2 | 32.29 Million USD | 2.64% |
2014 Q3 | 33.13 Million USD | 2.61% |
2014 FY | 32.82 Million USD | 27.37% |
2014 Q4 | 32.82 Million USD | -0.94% |
2014 Q1 | 31.46 Million USD | 22.09% |
2013 Q4 | 25.77 Million USD | 262.8% |
2013 FY | 25.77 Million USD | 4311.86% |
2013 Q2 | 2.01 Million USD | 7.74% |
2013 Q1 | 1.87 Million USD | 220.81% |
2013 Q3 | 7.1 Million USD | 251.81% |
2012 Q2 | 415.67 Thousand USD | 29.9% |
2012 Q4 | 584.17 Thousand USD | 7.34% |
2012 Q3 | 544.24 Thousand USD | 30.93% |
2012 FY | 584.17 Thousand USD | 62.57% |
2012 Q1 | 319.99 Thousand USD | -10.95% |
2011 Q1 | 1.11 Million USD | 84.81% |
2011 Q4 | 359.33 Thousand USD | -23.87% |
2011 Q3 | 471.99 Thousand USD | 11.05% |
2011 Q2 | 425.02 Thousand USD | -61.92% |
2011 FY | 359.33 Thousand USD | -40.5% |
2010 Q3 | 423.5 Thousand USD | 83.27% |
2010 FY | 603.95 Thousand USD | 71.06% |
2010 Q2 | 231.07 Thousand USD | 25.13% |
2010 Q4 | 603.95 Thousand USD | 42.61% |
2010 Q1 | 184.66 Thousand USD | -47.7% |
2009 FY | 353.07 Thousand USD | 15040.22% |
2009 Q1 | 38.09 Thousand USD | 1533.7% |
2009 Q2 | 38 Thousand USD | -0.24% |
2009 Q3 | 215.63 Thousand USD | 467.34% |
2009 Q4 | 353.07 Thousand USD | 63.74% |
2008 Q1 | 11.7 Thousand USD | 256.29% |
2008 FY | 2332.00 USD | -29.01% |
2008 Q4 | 2332.00 USD | 1133.86% |
2008 Q3 | 189.00 USD | 0.0% |
2008 Q2 | - USD | -100.0% |
2007 Q1 | 36.58 Thousand USD | -92.25% |
2007 Q3 | 4000.00 USD | -75.76% |
2007 Q4 | 3285.00 USD | -17.88% |
2007 Q2 | 16.5 Thousand USD | -54.9% |
2007 FY | 3285.00 USD | -99.3% |
2006 FY | 471.78 Thousand USD | 1351.65% |
2006 Q2 | 32.5 Thousand USD | 0.0% |
2006 Q4 | 471.78 Thousand USD | 1351.65% |
2006 Q3 | 32.5 Thousand USD | 0.0% |
2006 Q1 | 32.5 Thousand USD | 0.0% |
2005 Q1 | 340.72 Thousand USD | 0.06% |
2005 Q4 | 32.5 Thousand USD | -90.47% |
2005 Q3 | 341.1 Thousand USD | 0.06% |
2005 Q2 | 340.91 Thousand USD | 0.06% |
2005 FY | 32.5 Thousand USD | -90.46% |
2004 Q1 | 339.95 Thousand USD | 0.0% |
2004 Q3 | 340.34 Thousand USD | 0.06% |
2004 FY | 340.53 Thousand USD | 0.22% |
2004 Q2 | 340.15 Thousand USD | 0.06% |
2004 Q4 | 340.53 Thousand USD | 0.06% |
2003 FY | 339.76 Thousand USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
America Great Health | 4.82 Million USD | -10148.966% |
Ampio Pharmaceuticals, Inc. | 2.37 Million USD | -20712.668% |
Aridis Pharmaceuticals, Inc. | 38.92 Million USD | -1170.35% |
Biora Therapeutics, Inc. | 132.63 Million USD | -272.832% |
Bio-Path Holdings, Inc. | 2.77 Million USD | -17694.494% |
Better Therapeutics, Inc. | 23.84 Million USD | -1974.109% |
Calithera Biosciences, Inc. | 8.28 Million USD | -5869.447% |
Comera Life Sciences Holdings, Inc. | 9.97 Million USD | -4857.881% |
Gene Biotherapeutics, Inc. | - USD | -Infinity% |
eFFECTOR Therapeutics, Inc. | 26.33 Million USD | -1777.478% |
Eloxx Pharmaceuticals, Inc. | 31.78 Million USD | -1455.892% |
Evelo Biosciences, Inc. | 69.43 Million USD | -612.21% |
Evolutionary Genomics, Inc. | 7.94 Million USD | -6123.695% |
Finch Therapeutics Group, Inc. | 48.11 Million USD | -927.85% |
Galera Therapeutics, Inc. | 157.32 Million USD | -214.321% |
Innovation1 Biotech Inc. | 3.5 Million USD | -14004.826% |
Kiromic BioPharma, Inc. | 21.28 Million USD | -2222.751% |
Molecular Templates, Inc. | 31.17 Million USD | -1486.439% |
Navidea Biopharmaceuticals, Inc. | 12.51 Million USD | -3851.357% |
NexImmune, Inc. | 5.08 Million USD | -9626.326% |
Orgenesis Inc. | 35.53 Million USD | -1291.611% |
Panbela Therapeutics, Inc. | 16.51 Million USD | -2894.846% |
Point of Care Nano-Technology, Inc. | 266.41 Thousand USD | -185516.747% |
PaxMedica, Inc. Common Stock | 2.29 Million USD | -21444.116% |
Scopus BioPharma Inc. | 7.45 Million USD | -6533.756% |
Statera Biopharma, Inc. | 22.67 Million USD | -2080.716% |
TRACON Pharmaceuticals, Inc. | 10.91 Million USD | -4430.96% |
Trevena, Inc. | 48.26 Million USD | -924.634% |
Vaxxinity, Inc. | 30.94 Million USD | -1498.077% |
Vaccinex, Inc. | 5.94 Million USD | -8222.265% |
Vicapsys Life Sciences, Inc. | 1.96 Million USD | -25023.188% |
Viracta Therapeutics, Inc. | 38.37 Million USD | -1188.69% |
ZIVO Bioscience, Inc. | 2.76 Million USD | -17806.884% |